Peddayelachagiri Bhavani V, Paul Soumya, Makam Shivakiran S, Urs Radhika M, Kingston Joseph J, Tuteja Urmil, Sripathy Murali H, Batra Harsh V
Microbiology Division, Defence Food Research Laboratory, Mysore, Karnataka, India.
Microbiology Division, Defence Research and Development Establishment, Gwalior, Madhya Pradesh, India.
PLoS One. 2014 Mar 10;9(3):e90930. doi: 10.1371/journal.pone.0090930. eCollection 2014.
Burkholderia pseudomallei, the causative agent of melioidosis has been recognized by CDC as a category B select agent. Although substantial efforts have been made for development of vaccine molecules against the pathogen, significant hurdles still remain. With no licensed vaccines available and high relapse rate of the disease, there is a pressing need for development of alternate protection strategies. Antibody-mediated passive protection is promising in this regard and our primary interest was to unravel this frontier of specific mAbs against Burkholderia pseudomallei infections, as functional characterization of antibodies is a pre-requisite to demonstrate them as protective molecules. To achieve this, we designed our study on in vitro-based approach and assessed two mAbs, namely BURK24 and BURK37, reactive with outer membrane proteins and lipopolysaccharide of the pathogen respectively, for their ability to manifest inhibitory effects on the pathogenesis mechanisms of B. pseudomallei including biofilm formation, invasion and induction of apoptosis. The experiments were performed using B. pseudomallei standard strain NCTC 10274 and a clinical isolate, B. pseudomallei 621 recovered from a septicemia patient with diabetic ailment. The growth kinetic studies of the pathogen in presence of various concentrations of each individual mAb revealed their anti-bacterial properties. Minimal inhibitory concentration and minimal bactericidal concentration of both the mAbs were determined by using standards of Clinical and Laboratory Standards Institute (CLSI) and experiments were performed using individual mAbs at their respective bacteriostatic concentration. As an outcome, both mAbs exhibited significant anti-Burkholderia pseudomallei properties. They limited the formation of biofilm by the bacterium and completely crippled its invasion into human alveolar adenocarcinoma epithelial cells. Also, the mAbs were appreciably successful in preventing the bacterium to induce apoptosis in A549 cells. The present study design revealed the protection attributes possessed by BURK24 and BURK37 that has to be further substantiated by additional in vivo studies.
类鼻疽杆菌是类鼻疽病的病原体,已被美国疾病控制与预防中心认定为B类选择性生物制剂。尽管在开发针对该病原体的疫苗分子方面已付出巨大努力,但仍存在重大障碍。由于尚无获批的疫苗,且该病复发率高,迫切需要开发其他保护策略。抗体介导的被动保护在这方面很有前景,我们的主要兴趣在于揭示针对类鼻疽杆菌感染的特异性单克隆抗体这一前沿领域,因为抗体的功能表征是将其证明为保护性分子的先决条件。为实现这一目标,我们设计了基于体外方法的研究,并评估了两种分别与该病原体的外膜蛋白和脂多糖反应的单克隆抗体,即BURK24和BURK37,以研究它们对类鼻疽杆菌致病机制(包括生物膜形成、侵袭和诱导凋亡)的抑制作用。实验使用类鼻疽杆菌标准菌株NCTC 10274和从一名患有糖尿病的败血症患者身上分离出的临床菌株类鼻疽杆菌621进行。在存在不同浓度的每种单克隆抗体的情况下对该病原体进行生长动力学研究,揭示了它们的抗菌特性。使用临床和实验室标准协会(CLSI)的标准测定了两种单克隆抗体的最低抑菌浓度和最低杀菌浓度,并使用各自抑菌浓度的单克隆抗体进行实验。结果,两种单克隆抗体均表现出显著的抗类鼻疽杆菌特性。它们限制了该细菌生物膜的形成,并完全抑制了其对人肺泡腺癌上皮细胞的侵袭。此外,这些单克隆抗体在防止该细菌诱导A549细胞凋亡方面也相当成功。本研究设计揭示了BURK24和BURK37所具有的保护特性,这还需通过额外的体内研究进一步证实。